Executive Vice President
Clinical Research Division, Fred Hutch
Metcalfe Family/Frederick Appelbaum Endowed Chair in Cancer Research
Dr. Fred Appelbaum studies the biology and treatment of leukemias, lymphomas and other blood cancers and sees patients with these disorders. He has made numerous landmark contributions to his field. Notably, he helped develop Fred Hutch’s renowned program in blood stem cell transplantation. He also participated in the Hutch’s pioneering work to develop targeted antibody-based cancer therapies. Beyond his own research, Dr. Appelbaum has been a national leader in the conduct of clinical trials. In his current leadership role at the Hutch, Dr. Appelbaum sets the vision and standards for clinical research across the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium and oversees faculty affairs.
Dr. Appelbaum was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first antibody-drug conjugate approved by the Food and Drug Administration.
Professor, Division of Medical Oncology
University of Washington
Associate Director for Clinical Research
Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium
M.D., Tufts University, 1972
A.B. (cum laude), Dartmouth College, 1968
— Dr. Fred Appelbaum
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210